Sponsor pipeline

University of Michigan Rogel Cancer Center clinical trial pipeline

Get alerts when University of Michigan Rogel Cancer Center's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-10-16

What changed in the last 30 days

11 trials changed in the last 30 days: 0 stopped, 6 with notable changes, 5 with minor changes only.

  1. Notable

    Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy

    Phase changed: Phase 1 → not applicable

    Also in this update: Primary completion moved earlier from May 2028 to Dec 31, 2026; Study completion moved earlier from Nov 2028 to Jun 30, 2028

    University of Michigan Rogel Cancer CenterNot applicable NCT04518748 Registry history of NCT04518748 on ClinicalTrials.gov (opens the registry)

    Updated

Show 5 trials with minor changes only
  1. Minor

    Ribociclib Administered Concurrently With Postoperative Radiation Therapy · High-Risk, HR+/HER2- Breast Cancer

    Enrollment closed, study ongoing

    Also in this update: Primary completion pushed from Oct 2026 to Feb 2027; Study completion moved earlier from Oct 2030 to Feb 2030

    University of Michigan Rogel Cancer CenterPhase 1 NCT05996107 Registry history of NCT05996107 on ClinicalTrials.gov (opens the registry)

    Updated

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-10-08 NCT07864792 Transcranial Direct Current Stimulation to Improve Gait for Breast Cancer Survivor's Who… Not Yet Recruiting

Active trials by phase

Early Phase 1
1
Phase 1
7
Phase 1/2
5
Phase 2
20
Phase 4
1
Not charted: 29 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 63

NCT IDTitleConditionStatusUpdated
Phase 4
NCT05183126 Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With… Breast Cancer Recruiting 2026-07-02
Phase 2
NCT05901519 A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic… Hepatocellular Carcinoma Recruiting 2026-10-15
NCT03099356 Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory… Metastatic Thyroid Cancer Recruiting 2026-07-31
NCT07121595 Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the… Oral Cavity Squamous Cell Carcinoma Recruiting 2026-07-31
NCT06784336 Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in… Allogeneic Stem Cell Transplant Recruiting 2026-07-21
NCT06356155 Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer Urothelial Carcinoma Recruiting 2026-07-16
NCT07094685 Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck… Advanced Head and Neck Squamous Cell Carcinoma Recruiting 2026-06-26
NCT07158021 Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal… Anatomic Stage I Breast Cancer AJCC v8 Recruiting 2026-06-23
NCT05956041 Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell… Cutaneous T Cell Lymphoma Recruiting 2026-05-05
NCT07443943 A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in… Anatomic Stage 0 Breast Cancer AJCC v8 Recruiting 2026-04-24
NCT05894083 A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at… Oropharyngeal Cancer Recruiting 2026-02-02
NCT04858256 Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms T-Cell Neoplasm Recruiting 2026-01-29
NCT05038332 Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known… Prostate Cancer Recruiting 2026-01-16
NCT06580054 Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or… Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck Active, Not Recruiting 2026-07-29
NCT04140162 Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment… Multiple Myeloma Active, Not Recruiting 2026-07-28
NCT04748042 Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy… Prostate Cancer Active, Not Recruiting 2026-07-13
NCT06234748 Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer Oropharynx Cancer Active, Not Recruiting 2026-05-18
NCT05988918 Multicenter Trial of ESK981 in Patients With Select Solid Tumors Pancreatic Adenocarcinoma Active, Not Recruiting 2026-05-14
NCT04848337 Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer Prostate Cancer Metastatic Active, Not Recruiting 2026-05-11
NCT04574856 Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in… Glioblastoma Active, Not Recruiting 2026-03-25
NCT03787680 Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial) Prostate Cancer Active, Not Recruiting 2026-03-23
Phase 1/2
NCT06866262 Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic… Locally Advanced Clear Cell Renal Cell Carcinoma Recruiting 2026-07-31
NCT06616155 Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant… Castration-Resistant Prostate Carcinoma Recruiting 2026-05-05
NCT03781986 APG-115 in Salivary Gland Cancer Trial Malignant Salivary Gland Cancer Active, Not Recruiting 2026-07-13
NCT04194554 A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP… Prostate Cancer Active, Not Recruiting 2026-05-01

Disease areas by active trials, top 10 of 29

Get alerts when University of Michigan Rogel Cancer Center's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free